Burrill Life Sciences II Advisory Board

Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director,
Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate
in Chemistry

Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison

Jonathan Dordick—The Howard P. Isermann Professor in the Departments of Chemical and
Biological Engineering and Biology, Center for Biotechnology and Interdisciplinary Studies,
Rensselaer Polytechnic Institute

Alain Enthoven—Marriner S. Eccles Professor of Public and Private Management Emeritus at
the Stanford Graduate School of Business

Frederick Frank—Vice Chairman and Director, Lehman Brothers

Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex

Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman
of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation

Jeff Goldsmith—President, Health Futures

David M. Lawrence—Chairman and CEO (retired), Kaiser Foundation Health Plan and
Hospitals

Eric Lander—Director, Broad Institute of MIT and Harvard

Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately
held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine
and rhinitus.

George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona
State University; former CSTO and head of R&D, SmithKline Beecham

L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company; Managing Director
of Galen Partners, a late-stage healthcare private equity fund

Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)